1.
|
|
2.
|
|
3.
|
[DKFZ-2024-00634]
Journal Article
Tian, Y. ; Lin, Y. ; Qu, C. ; et al
Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk.We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. [...]
|
4.
|
[DKFZ-2024-00342]
Journal Article
Papadimitriou, N. ; Qu, C. ; Harrison, T. A. ; et al
Body size and risk of colorectal cancer molecular defined subtypes and pathways: Mendelian randomization analyses.
Obesity has been positively associated with most molecular subtypes of colorectal cancer (CRC); however, the magnitude and the causality of these associations is uncertain.We used Mendelian randomization (MR) to examine potential causal relationships between body size traits (body mass index [BMI], waist circumference, and body fat percentage) with risks of Jass classification types and individual subtypes of CRC (microsatellite instability [MSI] status, CpG island methylator phenotype [CIMP] status, BRAF and KRAS mutations). Summary data on tumour markers were obtained from two genetic consortia (CCFR, GECCO).A 1-standard deviation (SD:5.1 kg/m2) increment in BMI levels was found to increase risks of Jass type 1MSI-high,CIMP-high,BRAF-mutated,KRAS-wildtype (odds ratio [OR]: 2.14, 95% confidence interval [CI]: 1.46, 3.13; p-value = 9 × 10-5) and Jass type 2non-MSI-high,CIMP-high,BRAF-mutated,KRAS-wildtype CRC (OR: 2.20, 95% CI: 1.26, 3.86; p-value = 0.005). [...]
|
5.
|
|
6.
|
|
7.
|
|
8.
|
|
9.
|
|
10.
|
|